EGFR and cancer: Combining the current EGFR assay in a multiplex fashion with similar assays for IGF-1R and cMet could provide for optimal therapeutic choice and a drug resistance biomarker panel to drive targeted therapeutic efforts in NSCLC, as well as other cancers.